High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules

Cancer Research

Volumn 61, Issue 12, 2001, Pages 4750-4755

  Adams, Gregory P ^a   Schier, Robert ^b   McCall, Adrian M ^a   Simmons, Heidi H ^a   Horak, Eva M ^a   Alpaugh, R Katherine ^a   Marks, James D ^b   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ARTICLE; BINDING AFFINITY; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; INTERSTITIUM; KIDNEY CLEARANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIOIODINATION;

ANIMALS; ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; KIDNEY; KINETICS; MICE; MICE, INBRED STRAINS; MICE, SCID; OVARIAN NEOPLASMS; RABBITS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035874887     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors
2. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
3. A modeling analysis of monoclonal antibody percolation through tumors: A binding site barrier
4. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for binding site barrier
5. In vitro and in vivo characterization of a human anti-c-erB2 single chain Fv isolated from a filamentous phage antibody library
6. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
7. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv
8. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
9. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu
10. Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis
11. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors
12. 125I-antibody therapy efficacy in multicell spheroids
13. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
14. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies
15. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support
16. Redesigning nature's poisons to create antitumor reagents
17. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
18. Therapeutic application of antigrowth factor receptor, antibodies
19. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
20. Preclinical and Phase I and II trials of rituximab